Search Result

Isoforms Recommended:	GSK-3β

Results for "

GSK-3β

" in MedChemExpress (MCE) Product Catalog:

By Targets:	GSK-3 (96) AAK1 (1) Akt (2) AMPK (1) Amyloid-β (3) Antibiotic (4) Apoptosis (12) Aryl Hydrocarbon Receptor (1) Aurora Kinase (4) Autophagy (9) Bacterial (4) Beta-secretase (1) c-Myc (2) Calcium Channel (2) CDK (23) CFTR (1) Cholinesterase (ChE) (5) DYRK (5) ERK (2) HDAC (1) HIV (1) HSV (2) IAP (1) IKK (2) Integrin (1) Isotope-Labeled Compounds (1) JAK (4) JNK (2) Lipoxygenase (1) LRRK2 (1) MEK (2) Microtubule/Tubulin (1) Mitophagy (2) Organoid (2) p38 MAPK (2) Parasite (2) PDK-1 (1) Phosphatase (1) Phospholipase (1) PI3K (2) Pim (2) PKC (6) PROTACs (1) Proton Pump (2) RANKL/RANK (1) ROS Kinase (1) Src (1) Syk (1) Tau Protein (3) TGF-β Receptor (1) VEGFR (1) Wnt (2) β-catenin (4)
By Research Areas:	Cancer (63) Cardiovascular Disease (4) Infection (8) Inflammation/Immunology (14) Metabolic Disease (21) Neurological Disease (50)

By Targets:

GSK-3 (96)

AAK1 (1)

Akt (2)

AMPK (1)

Amyloid-β (3)

Antibiotic (4)

Apoptosis (12)

Aryl Hydrocarbon Receptor (1)

Aurora Kinase (4)

Autophagy (9)

Bacterial (4)

Beta-secretase (1)

c-Myc (2)

Calcium Channel (2)

CDK (23)

CFTR (1)

Cholinesterase (ChE) (5)

DYRK (5)

ERK (2)

HDAC (1)

HIV (1)

HSV (2)

IAP (1)

IKK (2)

Integrin (1)

Isotope-Labeled Compounds (1)

JAK (4)

JNK (2)

Lipoxygenase (1)

LRRK2 (1)

MEK (2)

Microtubule/Tubulin (1)

Mitophagy (2)

Organoid (2)

p38 MAPK (2)

Parasite (2)

PDK-1 (1)

Phosphatase (1)

Phospholipase (1)

PI3K (2)

Pim (2)

PKC (6)

PROTACs (1)

Proton Pump (2)

RANKL/RANK (1)

ROS Kinase (1)

Src (1)

Syk (1)

Tau Protein (3)

TGF-β Receptor (1)

VEGFR (1)

Wnt (2)

β-catenin (4)

By Research Areas:

Cancer (63)

Cardiovascular Disease (4)

Infection (8)

Inflammation/Immunology (14)

Metabolic Disease (21)

Neurological Disease (50)

126

Inhibitors & Agonists

Biochemical Assay Reagents

Peptides

Natural
Products

Recombinant Proteins

Isotope-Labeled Compounds

Antibodies

Targets Recommended: GSK-3

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-141480

GSK-3β inhibitor 3	GSK-3 Apoptosis	Cancer
GSK-3β inhibitor 3 is a potent, selective, irreversible and covalent inhibitor of Glycogen Synthase Kinase 3β (GSK-3β), with an IC₅₀ of 6.6 μM. GSK-3β inhibitor 3 can be used for the research of acute promyelocytic leukemia .

HY-130795

GSK-3β inhibitor 2 1 Publications Verification	GSK-3	Neurological Disease
GSK-3β inhibitor 2 (Compound 3) is a potent, selective and orally active *GSK-3β* inhibitor with an IC₅₀ of 1.1 nM. GSK-3β inhibitor 2 can cross the blood-brain barrier. GSK-3β inhibitor 2 has the potential for Alzheimer's disease .

HY-148133

GSK-3β inhibitor 12	GSK-3	Neurological Disease
GSK-3β inhibitor 12 (compound 15) is an inhibitor of *GSK-3β. GSK-3β inhibitor 12 inhibits 49.11% and 37.11% activity of 25 μM and 50 μM GSK-3β, respectively. GSK-3*β inhibitor 12 can be used for the research of neurodegenerative diseases .

HY-149542

GSK-3β inhibitor 15	Tau Protein Apoptosis GSK-3	Neurological Disease
GSK-3β inhibitor 15 (Compound 54) is a *GSK-3β* inhibitor (IC₅₀: 3.4 nM). GSK-3β inhibitor 15 inhibits Aβ_1-42-induced GSK-3β and tau protein phosphorylation. GSK-3β inhibitor 15 inhibits LPS-induced iNOS expression. GSK-3β inhibitor 15 has neuroprotective effects on Aβ_1-42-induced neurotoxicity. GSK-3β inhibitor 15 can be used for research of Alzheimer’s disease (AD) .

HY-143261

GSK-3β inhibitor 7	GSK-3	Metabolic Disease Inflammation/Immunology Cancer
GSK-3β inhibitor 7 is a *GSK-3β* inhibitor with an IC₅₀ value of 5.25 μM. GSK-3β inhibitor 7 is inserted into the ATP-binding binding pocket of GSK-3β and forms hydrogen-bond. GSK-3β inhibitor 7 shows high hepatocyte glucose uptake (83.5%), and can be used in the research of numerous diseases like diabetes, inflammation, cancer, Alzheimer's disease, and bipolar disorder .

HY-147134

GSK-3β inhibitor 10	GSK-3	Neurological Disease
GSK-3β inhibitor 10 (compound 14a) is a highly potent *GSK-3β* inhibitor with an IC₅₀ value of 80.5 nM. GSK-3β inhibitor 10 can be used for researching Alzheimer’s disease .

HY-143260

GSK-3β inhibitor 6	GSK-3	Metabolic Disease Inflammation/Immunology Cancer
GSK-3β inhibitor 6 is a potent *GSK-3β* inhibitor with an IC₅₀ value of 24.4 μM. GSK-3β inhibitor 6 shows high hepatocyte glucose uptake (38%). GSK-3β inhibitor 6 can be used in the research of numerous diseases like diabetes, inflammation, cancer, Alzheimer's disease, and bipolar disorder .

HY-120902

GSK-3β inhibitor 8	GSK-3	Inflammation/Immunology
GSK-3β inhibitor 8, a thiophenacil derivative, is an effective and selective inhibitor of *GSK-3β* (IC₅₀=64 nM). GSK-3β inhibitor 8 negatively regulated Wnt signaling pathway and stimulated β cell proliferation .

HY-148132

GSK-3β inhibitor 11	GSK-3	Neurological Disease
GSK-3β inhibitor 11 (compound 21) is a glycogen synthase kinase-3β (GSK-3β) inhibitor (IC₅₀=10.02 μM). GSK-3β inhibitor 11 can be used in neurodegenerative disease research .

HY-153760

GSK-3β inhibitor 14

GSK-3 Neurological Disease Metabolic Disease

GSK-3β inhibitor 14 (Compound 6i), benzothiazepinone derivative, is a weak GSK-3β inhibitor (IC₅₀ >100 μM) .

GSK-3β inhibitor 14	GSK-3	Neurological Disease Metabolic Disease
GSK-3β inhibitor 14 (Compound 6i), benzothiazepinone derivative, is a weak *GSK-3β* inhibitor (IC₅₀ >100 μM) .

HY-149054

GSK-3β inhibitor 13	GSK-3 Tau Protein AAK1 Pim PKC	Neurological Disease
GSK-3β inhibitor 13 (compound 47) is an orally active and potent *GSK-3β* inhibitor with blood-brain permeability. GSK-3β inhibitor 13 inhibits *GSK-3β* and *GSK-3α* with IC₅₀s of 0.73 nM and 0.35 nM, respectively. GSK-3β inhibitor 13 significantly decreases the phosphorylation of tau (IC₅₀=58 nM), which leads the formation of the neurofibrillary tangles associated with Alzheimer's disease .

HY-126144

GSK-3β inhibitor 1 2 Publications Verification	GSK-3	Metabolic Disease
GSK-3β inhibitor 1 (compound 3a) is a glycogen synthase kinase 3β (GSK-3β) inhibitor and demonstrates high antidiabetic efficacy, with an IC₅₀ of 4.9 nM .

HY-14679

GSK3β inhibitor II

GSK-3 Neurological Disease

GSK3β inhibitor II is an inhibitor of GSK3β. GSK3β inhibitor II can be used for research of Alzheimer’s disease (AD) .

GSK3β inhibitor II	GSK-3	Neurological Disease
GSK3β inhibitor II is an inhibitor of *GSK3β. GSK3*β inhibitor II can be used for research of Alzheimer’s disease (AD) .

HY-11012

TDZD-8 5+ Cited Publications GSK-3β Inhibitor I; NP 01139	GSK-3	Cancer
TDZD-8 is an inhibitor of *GSK-3β, with an IC₅₀* of 2 μM; TDZD-8 shows less potent activities against Cdk-1/cyclin B, CK-II, PKA, and PKC, with all IC₅₀s of >100 μM.

HY-10512

AR-A014418 10+ Cited Publications AR 0133418; GSK 3β inhibitor VIII; AR 014418	GSK-3	Metabolic Disease Cancer
AR-A014418 is a potent, selective and ATP-competitive *GSK3β* inhibitor (IC₅₀=104 nM; K_i=38 nM) .

HY-P1173

L803-mts Myristoylated L 803; GSK-3β Inhibitor XIII	GSK-3 Amyloid-β	Neurological Disease
L803-mts (Myristoylated L 803) is a selective and substrate-competitive *GSK-3* peptide inhibitor (IC₅₀: 40 μM). L803-mts also reduces Aβ deposits and ameliorates cognitive deficits in 5XFAD mice. L803-mts shows antidepressive effect in the forced swimming test .

HY-10512S

AR-A014418-d3 AR 0133418-d₃; GSK 3β inhibitor VIII-d₃; AR 014418-d₃	Isotope-Labeled Compounds GSK-3	Metabolic Disease Cancer
AR-A014418-d₃ is the deuterium labeled AR-A014418. AR-A014418 is a potent, selective, and ATP-competitive GSK3β inhibitor (IC50=104 nM; Ki=38 nM)[1].

HY-149845

*PROTAC GSK-3β Degrader-1*	GSK-3 PROTACs	Neurological Disease
PROTAC GSK-3β Degrader-1 (compound 1) is a degrader targets *GSK-3β* degradation with an IC₅₀ value of 833 nM. PROTAC GSK-3β Degrader-1 contains SB-216763 (a GSK-3β inhibitor), a PEG linker and a CRBN (E3 ligase liand). PROTAC GSK-3β Degrader-1 reduces the neurotoxicity induced by Aβ_25-35 peptide and CuSO₄. PROTAC GSK-3β Degrader-1 can be used to research in Alzheimer's disease .

HY-151260

*AChE/BACE1/GSK3β-IN-1*	Beta-secretase Cholinesterase (ChE) GSK-3	Neurological Disease
AChE/BACE1/GSK3β-IN-1 is an orally active triple inhibitor of *AChE/BACE1/GSK3β. AChE/BACE1/GSK3β-IN-1 has effective inhibitory activity against AChE, BACE1 and GSK3β with IC₅₀* values of 1.0 μM, 20 μM and 15 μM, respectively. AChE/BACE1/GSK3β-IN-1 has good blood-brain barrier penetrability, suitable bioavailability. AChE/BACE1/GSK3β-IN-1 can be used for the research of Alzheimer's disease (AD) .

HY-126144A

*(E/Z)-GSK-3β inhibitor 1*	GSK-3	Metabolic Disease
(E/Z)-GSK-3β inhibitor 1 is a racemic compound of (E)-GSK-3β inhibitor 1 and (Z)-GSK-3β inhibitor 1 isomers. GSK-3β inhibitor 1 (compound 3a) is a glycogen synthase kinase 3β (GSK-3β) inhibitor and demonstrates high antidiabetic efficacy, with an IC₅₀ of 4.9 nM .

HY-117194

18BIOder

HIV GSK-3 Infection

18BIOder is a neuroprotective GSK-3β inhibitor, highly selectively inhibiting HIV-1 .

18BIOder	HIV GSK-3	Infection
18BIOder is a neuroprotective *GSK-3β inhibitor, highly selectively inhibiting HIV*-1 .

HY-151375

*CDK9/10/GSK3β-IN-1*	Others	Cancer
CDK9/10/GSK3β-IN-1 (compound 13c) is a kinase inhibitor (Flavopiridol (HY-10005) analogue) that effectively inhibits *HsGSK3β* (IC₅₀=59 nM), HsCDK9/CyclinT (IC₅₀=64 nM), HsCDK5/p25 (IC₅₀=1.093 µM) and HsCDK2/CyclinA (IC₅₀=1.725 µM). CDK9/10/GSK3β-IN-1 has anti-cancer cellular activity comparable to or higher than that of Flavopiridol. CDK9/10/GSK3β-IN-1 shows high anti-proliferative activity in vitro against up to seven cancer cell lines .

HY-144290

ARN25068

GSK-3 DYRK Neurological Disease

ARN25068 is a sub-micromolar inhibitor of the three protein kinases, GSK-3β, FYN and DYRK1A to tackle tau hyperphosphorylation .

ARN25068	GSK-3 DYRK	Neurological Disease
ARN25068 is a sub-micromolar inhibitor of the three protein kinases, GSK-3β, FYN and DYRK1A to tackle tau hyperphosphorylation .

HY-144316

ZLWH-23	Cholinesterase (ChE) GSK-3	Neurological Disease
ZLWH-23 is a selective AChE inhibitor (IC₅₀=0.27 μM) with *GSK-3β* inhibitory property (IC₅₀=6.78 μM). ZLWH-23 possesses selectivity for AChE over BChE (IC₅₀=20.82 μM) and for GSK-3β over multi-kinases. ZLWH-23 has the potential for the research of Alzheimer's disease .

HY-137472

SAR502250	GSK-3	Neurological Disease
SAR502250 is a potent, selective, ATP competitive, orally active and brain-penetrant inhibitor of *GSK3, with an IC₅₀* of 12 nM for human GSK-3β. SAR502250 displays antidepressant-like activity. SAR502250 can be used for the research of Alzheimer’s disease (AD) .

HY-150537

*AChE/GSK-3β-IN-1*	Cholinesterase (ChE) GSK-3 Microtubule/Tubulin ROS Kinase	Neurological Disease
AChE/GSK-3β-IN-1 (compound GT15) is a potent, dual *AChE/GSK-3β* inhibitor with IC₅₀ values of 1.2, 149.8 and 22.4 nM for hAChE , hBChE and hGSK-3β, respectively. AChE/GSK-3β-IN-1 penetrates the blood-brain barrier (BBB). AChE/GSK-3β-IN-1 has high kinase selectivity profiles for the CMGC kinase family. AChE/GSK-3β-IN-1 occupies the ATP binding site of DYRK1A. AChE/GSK-3β-IN-1 inhibits ROS expression and reduces oxidative stress. AChE/GSK-3β-IN-1 can be used for Alzheimer’s disease research .

HY-10096

TCS2002	GSK-3	Neurological Disease
TCS2002 (Compound 9b) is a highly selective, orally bioavailable and potent *GSK-3β* inhibitor with the IC₅₀ of 35 nM. TCS2002 shows good pharmacokinetic profiles including favorable BBB penetration. TCS2002 can be used for the research of Alzheimer’s disease .

HY-14872

Tideglusib 5 Publications Verification NP031112	GSK-3	Neurological Disease
Tideglusib (NP031112) is an irreversible *GSK-3* inhibitor with IC₅₀s of 5 nM and 60 nM for GSK-3β ^WT (1 h preincubation) and GSK-3β ^C199A (1 h preincubation), respectively.

HY-12292

IM-12

5 Publications Verification

GSK-3 Cancer

IM-12 is an inhibitor of GSK-3β, with an IC₅₀ of 53 nM, and also enhances Wnt signalling.

IM-12 5 Publications Verification	GSK-3	Cancer
IM-12 is an inhibitor of *GSK-3β, with an IC₅₀* of 53 nM, and also enhances Wnt signalling.

HY-113914

9-ING-41 1 Publications Verification Elraglusib	GSK-3 Apoptosis Autophagy	Cancer
9-ING-41 (Elraglusib) is a maleimide-based ATP-competitive and selective glycogen synthase kinase-3β (GSK-3β) inhibitor with an IC₅₀ of 0.71 μM. 9-ING-41 significantly leads to cell cycle arrest, autophagy and apoptosis in cancer cells. 9-ING-41 has anticancer activity and has the potential for enhancing the antitumor effects of chemotherapeutic agents ^[3] .

HY-10590

TWS119 20+ Cited Publications	GSK-3 Autophagy	Neurological Disease Cancer
TWS119 is a specific inhibitor of *GSK-3β, with an IC₅₀* of 30 nM, and activates the wnt/β-catenin pathway.

HY-110074

TWS119 TFA

Others Others

TWS119 TFA is a specific inhibitor of GSK-3β, with an IC₅₀ of 30 nM, and activates the wnt/β-catenin pathway.

TWS119 TFA	Others	Others
TWS119 TFA is a specific inhibitor of *GSK-3β, with an IC₅₀* of 30 nM, and activates the wnt/β-catenin pathway.

HY-144826

ZDWX-25	GSK-3	Neurological Disease
ZDWX-25 is a highly potent *GSK-3β* and DYRK1A dual inhibitor with an IC₅₀ value of 71 nM for GSK-3β. ZDWX-25 possesses significant cytotoxic activities against SH-SY5Y and HL-7702 cells. ZDWX-25 can be used for researching alzheimer's disease .

HY-145669

DIF-3 1 Publications Verification	CDK GSK-3	Cancer
DIF-3 reduces the expression levels of cyclin D1 and c-Myc by facilitating their degradation via activation of *GSK-3β. DIF-3 inhibits Wnt/β-catenin signaling pathway-related proteins in DLD-1 cells. DIF*-3 exerts a strong antiproliferative effect on the human cervical cancer cell line HeLa by inducing cyclin D1 degradation and inhibiting cyclin D1 mRNA expression .

HY-B0320A

Cromolyn sodium 3 Publications Verification Disodium Cromoglycate; FPL-670	Calcium Channel GSK-3	Inflammation/Immunology
Cromolyn sodium (Disodium Cromoglycate; FPL-670) is an antiallergic agent. Cromolyn sodium is a *GSK-3β* inhibitor with an IC₅₀ of 2.0 μM.

HY-148561

CDK8-IN-12	CDK GSK-3 PKC	Cancer
CDK8-IN-12 is an orally active, potent CDK8 inhibitor with a K_i of 14 nM. CDK8-IN-12 has off-target kinase inhibition on GSK-3α, GSK-3β, PCK-θ with K_is of 13 nM, 4 nM, 109 nM, respectively. CDK8-IN-12 shows potent anti-proliferative effects selectively on MV4-11 cell. CDK8-IN-12 is an anti-cancer agent .

HY-154852

GSK-3 inhibitor 4	GSK-3 CDK	Neurological Disease
GSK-3 inhibitor 4 is an orally active and brain-penetrant inhibitor of *GSK-3, CDK2, and CDK5, with IC₅₀* values of 0.56 nM (GSK-3β), 0.45 nM (GSK-3α), 0.47 μM, and 0.68 μM, respectively. GSK-3 inhibitor 4 effectively reduces the phosphorylation level of Tau protein. GSK-3 inhibitor 4 can be used in Alzheimer's disease (AD) studies .

HY-107530

3F8	GSK-3	Cardiovascular Disease Metabolic Disease Cancer
3F8 is a potent and selective *GSK-3β* inhibitor that could be useful as new reagent and potential therapeutic candidate for GSK3 related diseases .

HY-124607B

BRD3731 1 Publications Verification	GSK-3	Neurological Disease Metabolic Disease
BRD3731 is a selective *GSK3β* inhibitor, with IC₅₀s of 15 nM and 215 nM for GSK3β and GSK3α, respectively. BRD3731 is potentail for the research of post-traumatic stress disorder (PTSD), psychiatric disorder, diabetes, and neurodegenerative disorders .

HY-12012

SB 216763 25+ Cited Publications	GSK-3 Autophagy	Neurological Disease Cancer
SB 216763 is potent, selective and ATP-competitive *GSK-3* inhibitor with IC₅₀s of 34.3 nM for both GSK-3α and GSK-3β.

HY-N0815

Resibufogenin 5+ Cited Publications Bufogenin; Recibufogenin	Others	Cancer
Resibufogenin, a component of huachansu, has been shown to exhibit the anti-proliferative effect against cancer cells, and this may be attributed to the degradation of cyclin D1 caused by the activation of GSK-3β.

HY-59090

1-Azakenpaullone 3 Publications Verification 1-Akp	GSK-3	Neurological Disease Metabolic Disease
1-Azakenpaullone (1-Akp) is a highly selective and ATP-competitive inhibitor of glycogen synthase kinase-3 β (GSK-3β), with an IC₅₀ value of 18 nM .

HY-100207

CP21R7 4 Publications Verification CP21	GSK-3	Cancer
CP21R7 is potent *GSK-3β* inhibitor, with an IC₅₀ of 1.8 nM; CP21R7 also shows inhibitory activitiy against PKCα, with an IC₅₀ of 1900 nM.

HY-16294

LY2090314 10+ Cited Publications	GSK-3	Cancer
LY2090314 is a potent inhibitor of glycogen synthase kinase-3 (GSK-3) with IC₅₀ values of 1.5 nM and 0.9 nM for GSK-3α and GSK-3β, respectively.

HY-111931

Indirubin-3'-monoxime-5-sulphonic acid	CDK GSK-3	Cancer
Indirubin-3'-monoxime-5-sulphonic acid is a potent and selective inhibitor of CDK1, CDK5, and *GSK-3β* with IC₅₀s of 5 nM, 7 nM, and 80 nM, respectively .

HY-B0320AR

Cromolyn sodium (Standard) Disodium Cromoglycate (Standard); FPL-670 (Standard)	Calcium Channel GSK-3	Inflammation/Immunology
Cromolyn (sodium) (Standard) is the analytical standard of Cromolyn (sodium). This product is intended for research and analytical applications. Cromolyn sodium (Disodium Cromoglycate; FPL-670) is an antiallergic agent. Cromolyn sodium is a *GSK-3β* inhibitor with an IC₅₀ of 2.0 μM.

HY-15761

AZD2858 5+ Cited Publications	GSK-3	Neurological Disease
AZD2858 is a potent, orally active *GSK-3* inhibitor, with IC₅₀s of 0.9 and 5 nM for *GSK-3α* and *GSK-3β*, respectively, used in the research of fracture healing.

HY-103221

MeBIO	Aryl Hydrocarbon Receptor GSK-3 CDK	Others
MeBIO is a potent AhR (aryl hydrocarbon receptor) agonist, with IC₅₀ of 44 μM (GSK-3) and 55 μM (CDK1/cyclin B), respectively. MeBIO is inactive on GSK-3β .

HY-122026

PF-04802367 PF-367	GSK-3	Neurological Disease
PF-04802367 (PF-367) is a highly selective *GSK-3* inhibitor with an IC₅₀ of 2.1 nM based on a recombinant human GSK-3β enzyme assay and 1.1 nM based on ADP-Glo assay. PF-04802367 shows desirable central nervous system (CNS) properties and potency. PF-04802367 is equally effective at inhibition of the two known GSK-3 isoforms (GSK-3α and *GSK-3β) with IC₅₀* values of 10.0 and 9.0 nM in mobility shift assays, respectively .

HY-15438

SB 415286 5+ Cited Publications	GSK-3 Apoptosis	Metabolic Disease
SB 415286 is a potent and selective cell permeable inhibitor of *GSK-3α, with an IC₅₀* of 77.5 nM, and a K_i of 30.75 nM; SB 415286 is equally effective at inhibiting human *GSK-3α* and *GSK-3β*.

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-N0815

Resibufogenin Maximum Cited Publications 6 Publications Verification Bufogenin; Recibufogenin	Classification of Application Fields Animals Source classification Disease Research Fields Steroids Cancer	Others
Resibufogenin, a component of huachansu, has been shown to exhibit the anti-proliferative effect against cancer cells, and this may be attributed to the degradation of cyclin D1 caused by the activation of GSK-3β.

HY-N8423

α-Amyrin 1 Publications Verification	Triterpenes Structural Classification other families Terpenoids Plants	ERK GSK-3
α-Amyrin is a pentacyclic triterpenoid compound with oral activity. α-Amyrin activates the ERK and *GSK-3β* signaling pathways. α-Amyrin can be used in the study of metabolic syndrome induced by high fructose diet and cognitive dysfunction caused by low cholinergic neurotransmission ^[3].

HY-117025A

Manzamine A hydrochloride 1 Publications Verification Keramamine A hydrochloride	Structural Classification Neurological Disease Classification of Application Fields Source classification Marine natural products Pyridine Alkaloids Indole Alkaloids Infection Alkaloids Piperidine Alkaloids Animals Sponge Disease Research Fields	GSK-3 CDK Parasite Proton Pump HSV Autophagy
Manzamine A hydrochloride, an orally active beta-carboline alkaloid, inhibits specifically *GSK-3β* and CDK-5 with IC₅₀s of 10.2 μM and 1.5 μM, respectively. Manzamine A hydrochloride targets vacuolar ATPases and inhibits autophagy in pancreatic cancer cells. Manzamine A hydrochloride has antimalarial and anticancer activities. Manzamine A hydrochloride also shows potent activity against HSV-1 ^[3] .

HY-N11576

Secalonic acid D	Structural Classification Natural Products Microorganisms Classification of Application Fields Sunscreen Source classification Cosmetic Research Disease Research Fields Cancer	Apoptosis GSK-3 c-Myc β-catenin
Secalonic acid D is a toxic compound against tumor cells. Secalonic acid D can be isolated from the metabolites of Aspergillus aculeatus. Secalonic acid D activates *GSK3-β, and degrades β-catenin. Thus, Secalonic acid D down-regulates c-Myc* expression, arrests cell cycle at G1 phase, induces cell apoptosis .

HY-117025

Manzamine A Keramamine A	Infection Alkaloids Structural Classification Neurological Disease Classification of Application Fields Animals Marine natural products Sponge Disease Research Fields Cancer	GSK-3 CDK Parasite Proton Pump HSV Autophagy
Manzamine A, an orally active beta-carboline alkaloid, inhibits specifically *GSK-3β* and CDK-5 with IC₅₀s of 10.2 μM and 1.5 μM, respectively. Manzamine A targets vacuolar ATPases and inhibits autophagy in pancreatic cancer cells. Manzamine A has antimalarial and anticancer activities. Manzamine A also shows potent activity against HSV-1 ^[3] .

HY-N6973

Boldine	Alkaloids Structural Classification Classification of Application Fields Source classification Phenols Polyphenols Plants Lauraceae Isoquinoline Alkaloids Inflammation/Immunology Disease Research Fields Litsea cubeba (Lour.) Pers.	RANKL/RANK Apoptosis
Boldine is an apomorphine isoquinoline alkaloid extracted from the root of the pheasant pepper (Litsea cubeba). Boldine is an oral effective antioxidant, anti-inflammatory, antitumor agent, and can inhibit osteoclast formation. Boldine induces apoptosis of human bladder cancer cells by regulating ERK, AKT and *GSK-3β. Boldine ameliorates bone destruction by down-regulating the OPG/RANKL/RANK* signaling pathway. It can be used in rheumatoid arthritis research ^[3].

HY-N6064

Polygalacin D 1 Publications Verification	Triterpenes Classification of Application Fields Terpenoids Source classification Platycodon grandiflorus (Jacq.) A. DC. Campanulaceae Plants Disease Research Fields Cancer	Apoptosis IAP
Polygalacin D (PGD) is a bioactive compound isolated from Platycodon grandiflorum with anticancer and anti-proliferative properties. PGD suppresses the expression of the IAP family of proteins including survivin, cIAP-1 and cIAP-2 and blocks the PI3K/Akt pathway by inhibiting the phosphorylation of GSK3β, Akt and the expression of PI3K. Polygalacin D induces apoptosis

HY-N7676

Marein	Cardiovascular Disease Flavonoids Chalcones other families Classification of Application Fields Neurological Disease Source classification Phenols Polyphenols Plants Disease Research Fields	AMPK HDAC
Marein has the neuroprotective effect due to a reduction of damage to mitochondria function and activation of the AMPK signal pathway. Marein improves insulin resistance induced by high glucose in HepG2 cells through CaMKK/AMPK/GLUT1 to promote glucose uptake, through IRS/Akt/GSK-3β to increase glycogen synthesis, and through Akt/FoxO1 to decrease gluconeogenesis. Marein is a HDAC inhibitor with an IC₅₀ of 100 µM. Marein has beneficial antioxidative, antihypertensive, antihyperlipidemic and antidiabetic effects ^[3].

HY-N7363

Isolongifolene (-)-Isolongifolene	Neurological Disease Classification of Application Fields Terpenoids Sesquiterpenes Source classification Rutaceae Murraya koenigii (L.) Spreng Plants Inflammation/Immunology Disease Research Fields	Apoptosis
Isolongifolene ((-)-Isolongifolene) is a tricyclic sesquiterpene isolated from Murraya koenigii. Isolongifolene attenuates Rotenone-induced oxidative stress, mitochondrial dysfunction and apoptosis through the regulation of PI3K/AKT/GSK-3β signaling pathways. Isolongifolene has antioxidant, anti-inflammatory, anticancer and neuroprotective properties .

Species:	Human (3) Mouse (1)
Tag:	His (3) GST (1)
Source:	Sf9 insect cells (3) P. pastoris (1)

Cat. No.	Compare	Product Name	Species	Source

HY-P73090

	GSK-3 beta Protein, Mouse (sf9, His) Glycogen synthase kinase-3 beta; GSK-3 beta; GSK3b	Mouse	Sf9 insect cells
	GSK-3 beta is a protein kinase that regulates cellular circadian rhythm, autophagy, and apoptosis. GSK-3 beta Protein, Mouse (sf9, His) is the recombinant mouse-derived GSK-3 beta protein, expressed by Sf9 insect cells , with N-10*His labeled tag. The total length of GSK-3 beta Protein, Mouse (sf9, His) is 420 a.a., with molecular weight of ~47 kDa.

HY-P74114

	GSK-3 beta Protein, Human (sf9, His) Glycogen synthase kinase-3 beta; GSK-3 beta; GSK3b	Human	Sf9 insect cells
	The TrkA protein is a receptor protein that binds to the neurotrophin nerve growth factor (NGF). It plays a crucial role in the development and survival of neurons. GSK-3 beta Protein, Human (sf9, His) is the recombinant human-derived GSK-3 beta protein, expressed by Sf9 insect cells , with N-His labeled tag. The total length of GSK-3 beta Protein, Human (sf9, His) is 433 a.a., with molecular weight of 44-48 kDa.

HY-P700591

	GSK-3 beta Protein, Human (P. pastoris, His) Serine/threonine-protein kinase GSK3B	Human	P. pastoris
	GSK-3 beta is an active protein kinase that regulates a variety of cellular processes. It negatively regulates glucose homeostasis, Wnt signaling, and transcription factors by phosphorylating substrates such as glycogen synthase, CTNNB1, and JUN. GSK-3 beta Protein, Human (P. pastoris, His) is the recombinant human-derived GSK-3 beta protein, expressed by P. pastoris , with N-6*His labeled tag. The total length of GSK-3 beta Protein, Human (P. pastoris, His) is 420 a.a., with molecular weight of 48.7 kDa.

HY-P702734

	GSK3B Protein, Human (sf9, GST) GSK3B; glycogen synthase kinase 3 beta; glycogen synthase kinase-3 beta; GSK-3 beta; GSK3beta isoform; serine/threonine-protein kinase GSK3B	Human	Sf9 insect cells

Cat. No.	Product Name	Chemical Structure

HY-10512S

AR-A014418-d3

AR-A014418-d₃ is the deuterium labeled AR-A014418. AR-A014418 is a potent, selective, and ATP-competitive GSK3β inhibitor (IC50=104 nM; Ki=38 nM)[1].

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks